58% kontra 61% (plasma HIV- 1 RNA < 400 kopier/ ml) – eller 46% kontra 50% (plasma HIV- 1 RNA < 50 kopier/ ml) ved uge 48 (sekundært efficacy end- point) i ” intent to treat ” (RD = F) - analysen.
58% versus 61% (plasma HIV-1 RNA < 400 copies/ ml) or 46% versus 50% (plasma HIV-1 RNA < 50 copies/ ml) at Week 48 (secondary efficacy endpoint) in the intent to treat (RD=F) analysis.